Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly, EVA Pharma Announce Regulatory Approval for Locally Manufactured Insulin
Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lilly, EVA Pharma Collaborate To Expand Baricitinib Access in Low-Income Nations
Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 09, 2024
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
